USE OF A SYNAPTIC VESICULAR PROTEIN INHIBITOR 2A (SV2A) OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION TO IMPROVE COGNITIVE FUNCTION, USE OF LEVITIRACETAM OR A PHARMACEUTICALLY ACCEPTABLE SALT AGAINST EFFECTIVELY, HEALTHY EFFECTIVELY EFFECTIVELY EFFECTIVE. USE OF SELETRACETAM OR A PHARMACEUTICALLY ACCEPTABLE SALT

摘要

use of a synaptic vesicular protein 2a (sv2a) inhibitor or a pharmaceutically acceptable salt thereof, pharmaceutical composition for improving cognitive function, use of levetiracetam or a pharmaceutically acceptable salt thereof, use of brivaracetam or a pharmaceutically acceptable salt thereof and use of seletracetam or a pharmaceutically acceptable salt thereof the present invention relates to the treatment of age-related cognitive impairment. this invention, in particular, relates to the use of synaptic vesicle protein (sv2a) inhibitors, such as levetiracetam, seletracetam and brivaracetam, in improving cognitive function in individuals who exhibit age-related cognitive impairment or are at risk of even, including, without limitation, individuals having or at risk for mild cognitive impairment (mci), age-related cognitive decline (arcd) or age-associated memory deficit (aami).